Cipla, leading drug maker, today announced that the company aims to build a strong presence in Kenya. In line with it's global strategy, Cipla continues to retain ownership of its marketing authorisations and trademarks for its products in Kenya and will continue to invest further in developing the Kenya market. The company has recently introduced its own office in Kenya. The products will be brought to Kenyan patients in partnership with Surgipharm.

Over the years, Cipla has been working with various partners in Kenya and has been supplying a basket of products across various key therapies - anti-HIV, anti-malarial, anti-asthma, gastroenterology, anti-infectives, cardiovascular and oncology among others.

Subhanu Saxena, MD & Global CEO, Cipla said, ''Our strong presence in Kenyan market will ensure that patients are able to receive affordable, high-quality medicines. Cipla is a company which provides one quality standard globally with manufacturing approvals from all the key international regulatory authorities.''

Shares of the company gained Rs 7.5, or 1.23%, to trade at Rs 619. The total volume of shares traded was 95,436 at the BSE (12.46 p.m., Monday).